InMed Pharmaceuticals annual depreciation and amortization
2020
2021
2022
2023
2024
2025
InMed Pharmaceuticals Depreciation & Amortization Growth & History (INM)
InMed Pharmaceuticals's depreciation and amortization was $212,839 for fiscal 2025.
View full InMed Pharmaceuticals company overviewInMed Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $212,839 | −$6,761 | −3.08% |
| 2024 | 2024-06-30 | $219,600 | $17,351 | +8.58% |
| 2023 | 2023-06-30 | $202,249 | $16,592 | +8.94% |
| 2022 | 2022-06-30 | $185,657 | $64,791 | +53.61% |
| 2021 | 2021-06-30 | $120,866 | $8,437 | +7.50% |
| 2020 | 2020-06-30 | $112,429 | — | — |
InMed Pharmaceuticals quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $51,707 | $1 | +0.00% |
| Q2 2026 | 2025-12-31 | $53,201 | −$1 | −0.00% |
| Q1 2026 | 2025-09-30 | $53,202 | −$1,377 | −2.52% |
| Q4 2025 | 2025-06-30 | $131,083 | — | — |
| Q3 2025 | 2025-03-31 | $51,706 | −$3,061 | −5.59% |
| Q2 2025 | 2024-12-31 | $53,202 | −$2,032 | −3.68% |
| Q1 2025 | 2024-09-30 | $54,579 | −$253 | −0.46% |
| Q3 2024 | 2024-03-31 | $54,767 | $4,078 | +8.05% |
| Q2 2024 | 2023-12-31 | $55,234 | $6,185 | +12.61% |
| Q1 2024 | 2023-09-30 | $54,832 | $5,784 | +11.79% |
| Q3 2023 | 2023-03-31 | $50,689 | −$2,651 | −4.97% |
| Q2 2023 | 2022-12-31 | $49,049 | −$748 | −1.50% |
| Q1 2023 | 2022-09-30 | $49,048 | $20,516 | +71.91% |
| Q3 2022 | 2022-03-31 | $53,340 | $25,919 | +94.52% |
| Q2 2022 | 2021-12-31 | $49,797 | $12,981 | +35.26% |
| Q1 2022 | 2021-09-30 | $28,532 | $551 | +1.97% |
| Q3 2021 | 2021-03-31 | $27,421 | $308 | +1.14% |
| Q2 2021 | 2020-12-31 | $36,816 | $8,584 | +30.41% |
| Q1 2021 | 2020-09-30 | $27,981 | −$2,246 | −7.43% |
| Q3 2020 | 2020-03-31 | $27,113 | — | — |
| Q2 2020 | 2019-12-31 | $28,232 | — | — |
| Q1 2020 | 2019-09-30 | $30,227 | — | — |
InMed Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, InMed Pharmaceuticals's depreciation and amortization increased from $112,429 to $212,839, a change of $100,410. The latest reported quarter, Q3 2026, shows $51,707.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review InMed Pharmaceuticals source filings ↗